|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on May 29, 2003; DOI 10.1182/blood-2002-12-3630.
Blood, 1 September 2003, Vol. 102, No. 5, pp. 1872-1876 Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphomaFrom the Department of Haematology, Centre Henri Becquerel, Rouen, France; EMI 9906-IRFMP no. 23, Centre Henri Becquerel, Rouen, France; and the Molecular Immunology Group, Tenovus laboratory, Southampton University Hospitals, Southampton, United Kingdom.
Translocations and somatic mutations are common genetic alterations of the BCL-6 gene on chromosome 3q27 in B-cell lymphoma, with implications for lymphomagenesis. The 2 events may have linked origins and can influence juxtaposed loci. To evaluate this further, we compared mutations occurring within the major mutation cluster region of the translocated and untranslocated BCL-6 alleles in 7 t(3;14)(q27;14q32) lymphomas. In 6 of 7 cases, the translocated allele revealed significantly higher mutations (mean, 5.8 x 10–2 bp–1) than did the untranslocated allele (mean, 5.3 x 10–3 bp–1; P < .01). The increase mapped to der(14q32), which retains the BCL-6 promoter and is transcriptionally active, as revealed by fusion transcripts and ongoing somatic mutations, absent in the der(3q27) region. These results indicate that enhanced mutational activity at the translocated allele may be a consequence of loss of cis regulatory elements or gain of IgH enhancer elements. Junctional sequences indicate translocation origins from earlier BCL-6 mutations and switch recombinase events.
The BCL-6 gene on chromosome 3q27 encodes a potent transcriptional repressor that regulates normal germinal center (GC) formation and function1 and is suggested as an important factor in lymphomagenesis.2 Rearrangements of this locus are common events in diffuse large B-cell lymphoma (DLBCL)3,4 and include chromosomal translocations mapping within the first noncoding BCL-6 exon and the first intron.4,5 A functional consequence is that regulatory and coding sequences on partner chromosomes are juxtaposed, generating a potential for aberrant gene expression on both rearranged partners.6,7 A second type of genetic alteration targeting this locus involves somatic mutations, which map to a region of approximately 2 kilobase (kb) downstream of the initiation site, encompassing the major mutation cluster (MMC).8,9 These can potentially dysregulate BCL-6 expression.10,11 There is some evidence to suggest that the 2 somatic events, that is, somatic mutations and translocations, may be related. A 120–base pair (bp) breakpoint hypercluster region located within the MMC12 displays a high BCL-6 mutational rate in lymphoma, with up to 35% of identifiable somatic mutations occurring in this region.13 Additional mechanisms may be involved. In t(3;14)(q27;q32) lymphomas, translocations usually involve the switch regions (SH) of the IgH locus, suggesting a role for the switch recombinase.12 This region also contains enhancer elements located 3' of the Cµ gene in IgH that affect somatic mutations in V genes.14 To assess the role of surrounding genetic elements on somatic mutation, we investigated the effects of the t(3;14) translocation on BCL-6 mutations by contrasting the untranslocated and translocated alleles in individual lymphoma cases. Junctional sequences were also analyzed to identify mechanisms likely to play a role in translocation origins.
Patient material We analyzed 7 lymphomas: 5 DLBCLs with more than 80% tumor cells and 2 follicular lymphomas (FLs) with more than 60% tumor cells, classified by World Health Organization criteria,15 each bearing the t(3;14) (3q27;14q32) translocation detected by conventional cytogenetic methods, with BCL-6 gene rearrangement confirmed by Southern blot analysis.2 Molecular analysis of BCL-6 To amplify the IgH/BCL-6 junctions, primers were designed according to the molecular anatomy of the t(3;14)(q27;q32) translocation described recently.12 To amplify the untranslocated allele, primers were designed to span the breakpoints (Figure 1). The polymerase chain reactions (PCRs) were performed using established conditions,16 and each product was cloned for sequence analysis. Identical amounts of DNA template ensured a comparable Taq polymerase rate error for both alleles, confirmed by repeated PCR analysis. In 4 of 4 cases with available RNA, fusion transcripts were detected by reverse transcriptase–PCR (RT-PCR) as previously described.7,17
Statistical analysis
The frequency of mutations occurring between the translocated and the
untranslocated allele were compared using the
In 7 of 7 cases, both the translocated and untranslocated alleles were amplified. Of the 7 t(3;14) translocations, reciprocal breakpoint regions were identified in 6 cases (Figures 1, 2), with der(14) not being found in 1 case (Table 1).
BCL-6 mutations were analyzed in each region. Polymorphic mutations (397G>C, 502G>A, or 520delT) allowed intra-allelic discrimination. Clonal mutations were observed. Mutations included point mutations and short additions and deletions (5 of 7 cases), biallelic mutations, and identical, recurrent mutations between cases (Table 1). Notably, a significant imbalance in the BCL-6 mutational load was observed between the translocated (mean, 5.8 x 10–2 bp–1) and the untranslocated (mean, 1.5 x 10–3 bp–1) allele in 6 of 7 cases (P < .01; Table 1 and Figure 2A). Mutations in BCL-6 can occur in the absence or presence of chromosomal rearrangements,8 but the influence of such events on mutational activity has not been delineated. These data show that in BCL-6, a dramatic increase in mutational rate can occur in t(3;14) lymphoma, which is preferentially targeted to the translocated allele. The data demonstrate clear differences in the level of BCL-6 mutations between the translocated and untranslocated alleles. This suggests that mechanistic constraints that regulate the level of mutational activity at the BCL-6 locus can be overcome in this case by involving IgH regulator elements. Whether this mutational activity results in higher levels of BCL-6 mutations as compared with lymphoma cases without the t(3;14) translocation lies outside the scope of this study, and large numbers of cases will clearly be required to reach statistical validity, for example, in correlating prognostic significance of BCL-6 mutations in lymphoma.18 By comparing BCL-6 mutations in both the derivative arms of the translocated allele, we obtained further insights into preferential targeting at this allele. Mutational activity in the translocated BCL-6 allele was notably in excess in der(14q32) compared with der(3q27), with 74% of mutations associating with der(14q32) (Table 1 and Figure 2B). The BCL-6 promoter is clearly transcriptionally active on der(14q32), as revealed by the presence of BCL-6–IgH fusion transcripts (2 of 4 cases; data not shown), and it is clear that transcription is a necessary prerequisite for somatic mutation.19 This suggests that enhancer elements downstream of the Cµ gene in IgH or loss of putative silencer elements in 3q27 affect the BCL-6 promoter and result in the high mutation rate observed in der(14q32). It reveals potential synergistic interaction between regulatory factors that control hypermutation at 2 different loci, BCL-6 and V genes. Furthermore, somatic mutations in BCL-6 in der(14q32) were apparently ongoing, as revealed by intraclonal heterogeneity at this site, but this was not true in der(3q27) in the same cases (Table 1 and Figure 2B). This argues for the acquisition of mutations after the chromosomal translocation event. Continuing mutational activity was also observed in the untranslocated allele, indicating biallelic targeting. The relationship between mutations in BCL-6 and V genes is not yet clear, but ongoing mutations are a feature of V genes in DLBCL or FL.20 Translocation of der(14q32) to other mutationally susceptible loci can potentially have an impact on mutations in partner genes, as in t(8;14) Burkitt lymphoma21 or in t(14;18) FL.22
The translocated breakpoints were identified. The MMC was directly involved
at the junction site in 4 of 7 cases (cases 1-4), with 3 of 7 cases mapping
downstream of MMC (Figure 1).
Translocation mapped to Sµ in 6 cases and in 1 case was located in S
Although switch events are involved in the translocated allele, we failed to find any homology with switch recognition motifs at the BCL-6 junction site on 3q27. This suggests involvement of additional proteins in addition to the switch recombinase. BCL-6 sequences at the junctional regions showed short deletions or duplications or precise double-stranded DNA breaks. Short-template insertions, sometimes with single substitutions, suggest a short-patch error-prone DNA synthesis. These features are consistent with a role for the hypermutation mechanism. A common enzyme, activation-induced cytidine deaminase, is required for V gene somatic mutation as well as switch recombination.24 Whether this key enzyme is implicated here in t(3;14) lymphoma is as yet not known. Our data show that at least 2 separate mechanisms, somatic mutation and isotype switch, underlie this frequent and important translocation in lymphoma.
Submitted December 3, 2002; accepted April 23, 2003.
Prepublished online as Blood First Edition Paper, May 29, 2003;
DOI 10.1182/blood-2002-12-3630.
Supported by the Leukaemia Research Fund (United Kingdom) and the Multiple
Myeloma Research Foundation (United States). F.J. was the recipient of a grant
from La Fondation De France.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked "advertisement" in accordance with 18 U.S.C. section
1734.
Reprints: Fabrice Jardin, Department of Haematology, Centre Henri Becquerel, 76000 Rouen, France; e-mail: fab.jardin{at}wanadoo.fr.
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
primers (Sµ 01F
5'-ggcaatgagatggctttagctg, Sµ 02F 5'-tgggctgagcaggttgtac, Sµ
01R 5'-tgccatgtccttccagttcatcc, S
2 test or the
Fisher exact test. 
